Business Description
Aldeyra Therapeutics is a Massachusetts-based biotechnology company focused on developing treatments for immune-related conditions. Its most advanced drug candidates include reproxalap, currently in late-stage trials for dry eye disease and eye allergies, and ADX-2191, which targets rare eye cancers and retinal disorders. The company is also testing an oral medication called ADX-629 for conditions ranging from asthma and psoriasis to COVID-19. Founded in 2004, Aldeyra continues to build a broader pipeline of experimental therapies aimed at addressing a wide range of inflammatory diseases.
